Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 500 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: erlotinib Clear all
Completed Phase 1Phase 2 Interventional Results available

Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer

NCT01211483
View directory record Official record
Conditions
NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions
U3-1287, Erlotinib, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
14
States / cities
Glendale, Arizona • Scottsdale, Arizona • Anaheim, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2021 · Synced Oct 17, 2026, 4:10 PM EDT
Completed Phase 2 Interventional

Erlotinib in Treating Patients With Metastatic and/or Recurrent Head and Neck Cancer

NCT00281866
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
erlotinib hydrochloride
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 12, 2016 · Synced Oct 17, 2026, 4:10 PM EDT
Terminated Phase 3 Interventional Results available

Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer

NCT00096265
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Brain, Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
Interventions
3-Dimensional Conformal Radiation Therapy, Erlotinib Hydrochloride, Stereotactic Radiosurgery, Temozolomide
Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
80
States / cities
Scottsdale, Arizona • Burbank, California • Los Angeles, California + 67 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2018 · Synced Oct 17, 2026, 4:10 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer

NCT01505530
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
LY2495655, Placebo, Standard of Care Chemotherapy
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Dallas, Texas • The Woodlands, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Oct 17, 2026, 4:10 PM EDT
Terminated Phase 1 Interventional Results available

A Safety Study in Participants With Advanced Solid Tumors

NCT01284335
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Gemcitabine, Docetaxel, Temozolomide, Cisplatin, Erlotinib, LY573636
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
19
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Oct 17, 2026, 4:10 PM EDT
Completed Phase 2 Interventional

Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00100854
View directory record Official record
Conditions
Lung Cancer
Interventions
erlotinib hydrochloride, fulvestrant
Drug
Lead sponsor
Translational Oncology Research International
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 17, 2026, 4:10 PM EDT
Completed Phase 1 Interventional

A Study of LY2875358 in Participants With Advanced Cancer

NCT01287546
View directory record Official record
Conditions
Advanced Cancer
Interventions
LY2875358, LY2875358 + erlotinib, LY2875358 at Part A highest dose, LY2875358 at Part A highest dose + trametinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
10
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2017 · Synced Oct 17, 2026, 4:10 PM EDT
Completed Phase 1 Interventional

Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid Tumors

NCT00085553
View directory record Official record
Conditions
Solid Neoplasm
Interventions
Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Tipifarnib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 18, 2018 · Synced Oct 17, 2026, 4:10 PM EDT
Completed Phase 2 Interventional Results available

Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer

NCT00940316
View directory record Official record
Conditions
Colorectal Cancer
Interventions
panitumumab, erlotinib hydrochloride, irinotecan hydrochloride
Biological · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
10
States / cities
Arlington Heights, Illinois • Chicago, Illinois • Joliet, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Oct 17, 2026, 4:10 PM EDT
Completed Phase 2 Interventional Results available

Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer

NCT00881751
View directory record Official record
Conditions
Liver Cancer
Interventions
bevacizumab, erlotinib hydrochloride, sorafenib tosylate
Biological · Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 116 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 17, 2026, 4:10 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery

NCT00242502
View directory record Official record
Conditions
Hepatocellular Carcinoma, Liver Cancer
Interventions
Bevacizumab (Avastin), Erlotinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2013 · Synced Oct 17, 2026, 4:10 PM EDT
Completed Phase 2 Interventional

A Study Comparing Sequential Satraplatin & Erlotinib to Erlotinib in Unresectable Stage 3/4 Non-small-cell Lung Cancer (NSCLC)

NCT00370383
View directory record Official record
Conditions
Lung Cancer
Interventions
Erlotinib, Satraplatin
Drug
Lead sponsor
Agennix
Industry
Eligibility
70 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
11
States / cities
Anaheim, California • La Jolla, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Oct 17, 2026, 4:10 PM EDT
Terminated Phase 2 Interventional Results available

Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera

NCT01038856
View directory record Official record
Conditions
Polycythemia Vera
Interventions
Erlotinib
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 24, 2020 · Synced Oct 17, 2026, 4:10 PM EDT
Completed Phase 2 Interventional Results available

Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma

NCT00754494
View directory record Official record
Conditions
Adenomatous Polyp, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage I Colon Cancer, Stage I Rectal Cancer, Stage IIA Colon Cancer, Stage IIA Rectal Cancer, Stage IIB Colon Cancer, Stage IIB Rectal Cancer, Stage IIC Colon Cancer, Stage IIC Rectal Cancer, Stage IIIA Colon Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer
Interventions
erlotinib hydrochloride, placebo, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Long Beach, California • Orange, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 6, 2015 · Synced Oct 17, 2026, 4:10 PM EDT
Terminated Phase 2 Interventional Results available

Erlotinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

NCT00387894
View directory record Official record
Conditions
Adult Brain Tumors
Interventions
erlotinib hydrochloride
Drug
Lead sponsor
Michael Prados
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Oct 17, 2026, 4:10 PM EDT
Completed Phase 1 Interventional

A Phase 1 Protocol of 5-Azacytidine and Erlotinib in Advanced Solid Tumor Malignancies

NCT00996515
View directory record Official record
Conditions
Advanced Solid Tumor Malignancies
Interventions
5-azacytidine, erlotinib, Erlotinib PO and Vidaza IV
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
19 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 1, 2013 · Synced Oct 17, 2026, 4:10 PM EDT
Completed Phase 2 Interventional Results available

Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer

NCT00126581
View directory record Official record
Conditions
Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Malignant Pericardial Effusion, Malignant Pleural Effusion, Minimally Invasive Lung Adenocarcinoma, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Carboplatin, Erlotinib, Erlotinib Hydrochloride, Paclitaxel
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
96
States / cities
Castro Valley, California • Emeryville, California • Fremont, California + 68 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Oct 17, 2026, 4:10 PM EDT
Completed Phase 1 Interventional

An Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation Status

NCT00903734
View directory record Official record
Conditions
Advanced Cancers
Interventions
Erlotinib Hydrochloride (Tarceva)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2015 · Synced Oct 17, 2026, 4:10 PM EDT
Completed Phase 2 Interventional Results available

Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck

NCT00720304
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
docetaxel, erlotinib hydrochloride, fluorescence in situ hybridization, polymerase chain reaction, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, therapeutic conventional surgery, intensity-modulated radiation therapy, radiation therapy
Drug · Genetic · Other + 2 more
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 17, 2026, 4:10 PM EDT
Terminated Phase 2 Interventional

A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung Cancer

NCT00283634
View directory record Official record
Conditions
NSCLC
Interventions
erlotinib and bortezomib
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 17, 2011 · Synced Oct 17, 2026, 4:10 PM EDT
Completed Phase 1 Interventional

Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC

NCT00633529
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
IMO-2055
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
9
States / cities
Ocoee, Florida • Indianapolis, Indiana • Albany, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2013 · Synced Oct 17, 2026, 4:10 PM EDT
Completed Phase 2 Interventional

A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial

NCT02057380
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
linsitinib, erlotinib, paclitaxel, Bortezomib, Dexamethasone
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
La Jolla, California • Tampa, Florida • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 17, 2026, 4:10 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising Prostate Specific Antigen (PSA) on Hormone Therapy

NCT00148772
View directory record Official record
Conditions
Prostate Cancer
Interventions
Erlotinib (Tarceva)
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years and older · Male only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
2
States / cities
Chicago, Illinois • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 28, 2011 · Synced Oct 17, 2026, 4:10 PM EDT
Terminated Phase 2 Interventional Results available

Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma

NCT01009203
View directory record Official record
Conditions
Squamous Cell Carcinoma
Interventions
Erlotinib, Temsirolimus
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Aug 10, 2015 · Synced Oct 17, 2026, 4:10 PM EDT